3 ms·
California to begin selling affordable state-branded insulin beginning next year
- toomuchtodo 1y agoRelated: California governor vetoes bill that would have set a $35 cap for insulin - https://news.ycombinator.com/item?id=37815862 https://news.ycombinator.com/item?id=37815862 - October 2023 (139 comments) California’s Plan for Cheaper Insulin Collides with Big Pharma’s Price Cuts - https://news.ycombinator.com/item?id=35325942 https://news.ycombinator.com/item?id=35325942 - March 2023 (2 comments) California's Own Brand of Insulin - https://news.ycombinator.com/item?id=35220390 https://news.ycombinator.com/item?id=35220390 - March 2023 (0 comments) Insulin is way too expensive. California has a solution: Make its own - https://news.ycombinator.com/item?id=34726726 https://news.ycombinator.com/item?id=34726726 - February 2023 (258 comments) California aims to make its own insulin brand to lower price - https://news.ycombinator.com/item?id=32311465 https://news.ycombinator.com/item?id=32311465 - August 2022 (29 comments) Governor Newsom announces California will make its own insulin - https://news.ycombinator.com/item?id=32021868 https://news.ycombinator.com/item?id=32021868 - July 2022 (216 comments) California aims to slash insulin prices - https://news.ycombinator.com/item?id=31649237 https://news.ycombinator.com/item?id=31649237 - June 2022 (208 comments)
- JumpCrisscross 1y ago> bill that would have set a $35 cap for insulin Because this worked so well for home insurance. $35 in 2025 dollars buys as much as $32.92 in 2023 dollars [1]. At what point does it become unprofitable for anyone to manufacture and deliver? (Not the out-of-patent stuff nobody wants to take that can be made for $3/vial. The long-acting and ultra-fast formulations people actually use when given a choice.) And unlike with home insurance, in an insulin shortage, people die. You need a CalFIRE mechanism, a seller of last resort, who will purchase the insulin at any price on the market and sell it at $35 for such a scheme to work. State-controlled production removes that surprise factor. It's a much better system than price regulation. [1] https://www.usinflationcalculator.com https://www.usinflationcalculator.com
- deleted 1y ago[deleted]
- hodgehog11 1y agoThe difference is that the proposed caps for home insurance would have made the product unprofitable, no question. My understanding is that there is no way any vial of insulin anywhere, at this point in time, should cost enough to produce for US$35 asking price to be unprofitable. See [1] and [2] for example. This would need to increase with inflation, of course. Regardless, the bill didn't pass. Arguments like this were probably the reason why. [1] https://www.mayoclinicproceedings.org/article/S0025-6196(21)00883-1/abstract https://www.mayoclinicproceedings.org/article/S0025-6196(21)... [2] https://www.medcentral.com/endocrinology/diabetes/the-high-costs-of-insulin https://www.medcentral.com/endocrinology/diabetes/the-high-c...
- dragonwriter 1y ago> My understanding is that there is no way any vial of insulin anywhere, at this point in time, should cost enough to produce for US$35 asking price to be unprofitable. The vetoed bill (SB 90 of 2023) did not address the price of insulin, only the allowable insurance copay for insulin. The fact that this, without addressing the actual price, would just shift the costs from copays to premiums was called out in the veto message. Also note that, with CalRx's insulin initiative ready to deliver at the same time the bill goes into effect, SB 40 of 2025 which set the same copay cap as SB 90 of 2023, was signed by Newsom this week.
- jrflowers 1y ago> The long-acting and ultra-fast formulations people actually use when given a choice. The patent for insulin glargine (Lantus) and insulin aspart (NovoLog) expired over a decade ago, though kind of amusingly Sanofi holds an active patent on “putting more Lantus in a vial than you usually would” https://patents.google.com/patent/US9345750B2/en https://patents.google.com/patent/US9345750B2/en I could be wrong but off the top of my head the only insulin I can think of that’s probably under patent is Afrezza, which is cool as hell because it’s inhalable and ultra-quick
- h4kunamata 1y ago[flagged]
- abeindoria 1y agoUS isn't a singular entity. A bunch of states do quite a lot for their populace in general.
- dragonwriter 1y ago> US caring about affordable health care in any way? X is true of the US as a whole, and California is part of the US, so X must be true of California is an example of the Fallacy of Division.
- tomhow 1y agoPlease don't post snark on HN. The guidelines make it clear that we're trying for something better here. https://news.ycombinator.com/newsguidelines.html https://news.ycombinator.com/newsguidelines.html
- jerlam 1y agoI want to know the economics of this, especially since California is partnering with the actual company that's building and running the factories. Is this insulin expected to sell at a profit? Break-even? Or is California just spending its own money to get the price point down?
- dragonwriter 1y agoThe biosimilar insulin initiative is by design priced to cover end-to-end costs (the CalRx own program costs and the cost to manufacture); the main contracted manufacturer (CivicaRx) is also a nonprofit generic drug manufacturer, but the initial supply that will be available in January is something they've subcontracted with Biocon Biologics for (my understanding is that this is because the Biocon product already has FDA clearance, whereas regulatory clearance for CivicaRx's product is still pending, though the manufacturing is up and running.)
- dragonwriter 1y agoThe biosimiliar insulin initiative is a very big deal, but for context it is not CalRx's first effort to reach public availability. That was the Naloxone Initiative, which made OTC naloxone (generic for Narcan), which hit the market last year at about 40% below the pre-existing market price, and has dropped further since.